Foraco International And 2 Other TSX Penny Stocks To Watch

The Canadian market is navigating a complex landscape, with trade developments and central bank decisions poised to influence economic momentum and investor sentiment. Amid these broader market dynamics, penny stocks remain an intriguing segment for investors looking to uncover potential growth opportunities outside the mainstream. While the term "penny stock" might seem outdated, it still captures the essence of investing in smaller or newer companies that can offer significant returns when supported by strong financial fundamentals.

Top 10 Penny Stocks In Canada

Click here to see the full list of 880 stocks from our TSX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Foraco International (TSX:FAR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Foraco International SA, with a market cap of CA$157.81 million, offers drilling services across North America, South America, the Asia Pacific, the Middle East, Africa, and Europe.

Operations: The company's revenue is derived from two main segments: Mining, which contributes $229.998 million, and Water, accounting for $41.376 million.

Market Cap: CA$157.81M

Foraco International SA, with a market cap of CA$157.81 million, has shown stable financial management despite recent challenges. Its revenue from mining and water segments indicates it is not pre-revenue, though Q1 2025 sales dropped to US$55.01 million from US$77.09 million the previous year, impacting net income significantly. The company's debt is well-covered by operating cash flow and its short-term assets exceed both long-term and short-term liabilities, indicating solid liquidity management. However, high net debt to equity ratio remains a concern alongside negative earnings growth last year despite significant profit growth over five years and high-quality earnings overall.

• Take a closer look at Foraco International's potential here in our financial health report.
• Explore Foraco International's analyst forecasts in our growth report.

Roots (TSX:ROOT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Roots Corporation, along with its subsidiaries, is involved in designing, marketing, and selling apparel, leather goods, footwear, and accessories under the Roots brand both in Canada and internationally; it has a market cap of CA$123.25 million.

Operations: The company's revenue is primarily generated through its Direct-To-Consumer segment, which accounts for CA$223.26 million, complemented by CA$39.66 million from Partners and Other sources.

Market Cap: CA$123.25M

Roots Corporation, with a market cap of CA$123.25 million, has demonstrated financial resilience despite ongoing challenges. The company reported Q1 2025 sales of CA$39.98 million, an increase from the previous year, while reducing its net loss to CA$7.91 million. Short-term assets exceed short-term liabilities by CA$26.3 million, indicating solid liquidity management; however, long-term liabilities remain uncovered by these assets. Roots' debt is well-managed with satisfactory net debt to equity and is supported by operating cash flow covering 78% of its debt obligations. Despite being unprofitable with a negative return on equity, Roots has reduced losses over the past five years significantly and recently initiated a share buyback program to enhance shareholder value.

• Navigate through the intricacies of Roots with our comprehensive balance sheet health report here.
• Gain insights into Roots' outlook and expected performance with our report on the company's earnings estimates.

Thiogenesis Therapeutics (TSXV:TTI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company focused on developing thiol-based therapeutic compounds for unmet pediatric medical needs, with a market cap of CA$35.66 million.

Operations: Thiogenesis Therapeutics, Corp. has not reported any revenue segments.

Market Cap: CA$35.66M

Thiogenesis Therapeutics, Corp., with a market cap of CA$35.66 million, is navigating the pre-revenue phase as it focuses on developing treatments for rare pediatric diseases. The company recently announced FDA clearance for its investigational drug TTI-0102, targeting Leigh syndrome spectrum and plans to start a Phase 2a clinical trial in collaboration with the Children's Hospital of Philadelphia. Despite being debt-free and having sufficient cash runway for over a year, Thiogenesis faces challenges with increasing losses and high share price volatility. Its board is experienced, though profitability remains elusive as it advances its clinical trials.

• Unlock comprehensive insights into our analysis of Thiogenesis Therapeutics stock in this financial health report.
• Understand Thiogenesis Therapeutics' track record by examining our performance history report.

Key Takeaways

• Access the full spectrum of 880 TSX Penny Stocks by clicking on this link.
• Ready To Venture Into Other Investment Styles? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com